Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel To Discuss “Breakpoint” Changes For Systemic Antibiotics

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-Infective Drugs Advisory Committee will meet Oct. 17 to discuss whether and when it is appropriate to base susceptibility test interpretive criteria on the highest or lowest approved dose of a drug, or whether labeling should reflect breakpoints specific to each approved dosing regimen and indication.

You may also be interested in...

Cubist Tedizolid Advisory Cmte. Review Will Gauge FDA’s Mood On Antibiotic “Breakpoints”

Cubist’s second-generation oxazolidineone is set for an FDA advisory committee review in March.

FDA Panel Sees Role For PK/PD Modeling In Revising Antibiotic “Breakpoints”

In certain circumstances it may be appropriate to change the criteria for determining when a pathogen is susceptible to a drug and recommended doses for systemic antibacterials absent clinical outcomes data, Anti-Infective Drugs Advisory Committee says.

Drug Makers Face Higher Relabeling Burden For Antibacterial Resistance Info

FDA plans to issue a yearly update on the susceptibility of bacteria to treatment by individual antibiotics and has drafted guidance that calls on drug makers to revise labeling for systemic antibacterial products accordingly

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts